Advertisement


Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

ESMO Virtual Congress 2020

Advertisement

Masahiro Tsuboi, MD, of Japan’s National Cancer Center Hospital East, discusses the phase III results from the ADAURA study, which showed a reduced risk of local and distant recurrence in patients with resected EGFR-mutated non–small cell lung cancer, reinforcing adjuvant osimertinib as an effective treatment (Abstract LBA1).



Related Videos

Breast Cancer
Immunotherapy

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses results from the phase III ASCENT trial, which showed the antibody-drug conjugate sacituzum...

Skin Cancer
Immunotherapy

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Jeffrey S. Weber, MD, PhD, of the Perlmutter Cancer Center, NYU Langone, discusses the 4-ye...

Breast Cancer

Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease

Erika P. Hamilton, MD, of Sarah Cannon Research Institute, discusses results of the nextMONARCH study, which indicated that combining abemaciclib with tamoxifen improved over...

Lung Cancer

David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

David S. Hong, MD, of The University of Texas MD Anderson Cancer Center, discusses study findings on sotorasib, a novel, first-in-class, oral KRASG12C inhibitor. The agent de...

Gynecologic Cancers

Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin

Andreas du Bois, MD, PhD, of Kliniken Essen Mitte, discusses the NORA and INOVATYON studies of patients with recurrent ovarian cancer, detailing the findings for women in Chi...

Advertisement

Advertisement



Advertisement